The CD19 signalling molecule is elevated in NOD mice and controls type 1 diabetes development

Area of Science:

• Immunology
• Endocrinology
• Diabetes Research

Background:

• Type 1 diabetes involves insulitis and beta cell destruction, with early stages marked by peri-islet inflammation and autoantibodies.
• The precise immunological triggers for invasive insulitis remain incompletely understood.
• B cells are implicated in autoimmune diabetes pathogenesis, but their specific roles in initiating invasive insulitis require further elucidation.

Purpose of the Study:

• To test the hypothesis that B cells in diabetes-prone NOD mice drive invasive insulitis via enhanced CD19 expression.
• To investigate how CD19 influences the uptake and presentation of beta cell antigens to islet-specific T cells.
• To explore the therapeutic potential of targeting CD19 in preventing autoimmune diabetes progression.

Main Methods:

• Compared CD19 expression and signaling in B cells from NOD and control mice.
• Assessed CD8(+) T cell expansion specific for beta cell antigens (IGRP, insulin) in CD19-deficient versus wild-type NOD mice.
• Correlated insulitis severity with T cell responses and evaluated anti-CD19 therapy efficacy.

Main Results:

• NOD mice exhibited increased CD19 expression and signaling in B cells.
• CD19 deficiency significantly reduced CD8(+) T cell expansion against the membrane-bound antigen IGRP.
• A less pronounced reduction was observed for T cells targeting the soluble antigen insulin.

Conclusions:

• Elevated CD19 on B cells in NOD mice facilitates presentation of membrane-bound antigens like IGRP, promoting autoreactive T cell expansion critical for invasive insulitis.
• Targeting the CD19 signaling pathway in individuals with insulin autoantibodies before T1DM onset could prevent islet-invasive T cell expansion.
• This approach may offer a strategy to preserve beta cell mass and prevent type 1 diabetes development.